Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

The aim of this study was to compare 2 stepwise covariate model-building strategies, frequently used in the analysis of pharmacokinetic-pharmacodynamic (PK-PD) data using nonlinear mixed-effects models, with respect to included covariates and predictive performance. In addition, the effects of stepwise regression on the estimated covariate coefficients wise regression on the estimated covariate coefficients were assessed. Using simulated and real PK data, covariate models were built applying (1) stepwise generalized additive models (GAM) for identifying potential covariates, followed by backward elimination in the computer program NONMEM, and (2) stepwise forward inclusion and backward elimination in NONMEM. Different versions of these procedures were tried (eg, treating different study occasions as separate individuals in the GAM, or fixing a part of the parameters when the NONMEM procedure was used). The final covariate models were compared, including their ability to predict a separate data set or their performance in cross-validation. The bias in the estimated coefficients (selection bias) was assessed. The model-building procedures performed similarly in the data sets explored. No major differences in the resulting covariate models were seen, and the predictive performances overlapped. Therefore, the choice of model-building procedure in these examples could be based on other aspects such as analyst-and computer-time efficiency. There was a tendency to selection bias in the estimates, although this was small relative to the overall variability in the estimates. The predictive performances of the stepwise models were also reasonably good. Thus, selection bias seems to be a minor problem in this typical PK covariate analysis.

[1]  Alan J. Miller,et al.  Subset Selection in Regression , 1991 .

[2]  Alan J. Miller Subset Selection in Regression , 1992 .

[3]  H. Keselman,et al.  Backward, forward and stepwise automated subset selection algorithms: Frequency of obtaining authentic and noise variables , 1992 .

[4]  James E. Bennett,et al.  The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .

[5]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[6]  E W Steyerberg,et al.  Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. , 1999, Journal of clinical epidemiology.

[7]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[8]  Lewis B. Sheiner,et al.  Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients , 1999, Antimicrobial Agents and Chemotherapy.

[9]  N. Holford,et al.  The pharmacokinetics of theophylline in premature neonates during the first few days after birth. , 1999, Therapeutic drug monitoring.

[10]  G. Anderson,et al.  Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy , 2000, Epilepsy Research.

[11]  H. Zhou,et al.  Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. , 2000, British journal of clinical pharmacology.

[12]  J. Habbema,et al.  Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. , 2000, Statistics in medicine.

[13]  L. Grochow,et al.  Population pharmacokinetic model for topotecan derived from phase I clinical trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Trocóniz,et al.  Pharmacokinetic-Pharmacodynamic Modelling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen , 2000, Clinical pharmacokinetics.

[15]  I. Court-Fortune,et al.  Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. , 2000, British journal of clinical pharmacology.

[16]  M. Tempero,et al.  Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil , 2000, Cancer Chemotherapy and Pharmacology.

[17]  D. Ouellet,et al.  Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer , 2000, Cancer Chemotherapy and Pharmacology.

[18]  Tomohiro Sudo,et al.  Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study , 2001, Cancer Chemotherapy and Pharmacology.

[19]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[20]  Willi Sauerbrei,et al.  Variable Selection and Shrinkage: Comparison of Some Approaches , 2001 .

[21]  Peter L. Bonate,et al.  The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models , 1999, Pharmaceutical Research.

[22]  Mats O. Karlsson,et al.  Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.

[23]  M. Hutmacher,et al.  Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  Donald R. Stanski,et al.  Evaluation of population (NONMEM) pharmacokinetic parameter estimates , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  D. Stanski,et al.  A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  Alain Durand,et al.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.